@entity1259 is an agent with a lower incidence of @entity1370 and myelotoxicity compared with @entity632 ; and it is active in @entity1 with @entity1893 ( @entity1893 ). Our aim was to define the therapeutic efficacy and @entity137 of dose-intensified @entity1259 in combination with @entity786 , @entity1891 , and @entity229 (CEOP) in @entity1 with diffuse large-cell @entity1893 . Previously untreated @entity1 aged between 15 and 75 years, with at least one measurable lesion, adequate liver, renal, cardiac functions, and no central nervous system involvement were included in the study. The planned chemotherapy regimen CEOP consisted of @entity786 750 mg/m2, @entity1259 100 mg/m2, and @entity1891 1.4 mg/m2 intravenously on day 1 and 100 mg @entity229 taken orally on days 1 to 5. Courses were repeated every 21 days. @entity1 with stage I and II received four cycles of chemotherapy followed by involved-field radiotherapy, and @entity1 with stage III and IV received six cycles of chemotherapy followed by radiotherapy to bulky lymph node sites. Seventy-five @entity1 were enrolled in the study. The complete response rate was 83.8%, and 72 @entity1 were assessable for @entity137 . The most common @entity137 was myelosuppression; 13.9% of the @entity1 had grade III-IV @entity1398 . Severe @entity33 , @entity294 , and @entity391 were uncommon (<10%). At a median follow-up period of 41 months, the 5-year progression-free survival and overall survival rates were 63.5% and 65.3%, respectively. Increasing the dose intensity of @entity1259 can yield a similar complete response rate compared with the regimens used in @entity1893 without significantly increasing the @entity137 rate associated with chemotherapy. The role of dose-intensive @entity1259 should be investigated further in future randomized trials.

Treatment of aggressive @entity1893 with dose-intensified @entity1259 in combination of @entity786 , XXXX , and @entity229 (CEOP-100): a phase II study.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin', 'Epirubicin'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity391 :: ('MESH:D014839', 'Disease') :: ['emesis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxicity']
@entity1891 :: (MESH:D014750,Chemical) :: ['vincristine']
